About Atherotech
Atherotech is a Healthcare company based in Birmingham (United States) founded in 1994, and was acquired by Behrman Capital in January 2011. It develops cardiometabolic testing and disease management solutions. The company has 335 employees. Atherotech offers products and services including News Platform and Newsletter Service. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, In-Vitro Diagnostics and Diversified. Its legal entity is ATHEROTECH, INC. Its competitors include SpectraWAVE, Proxim Diagnostics and Boston Heart Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Atherotech was founded in 1994 in Birmingham, United States, within the healthcare sector. Comprehensive lipid profiles were measured directly through the patented VAP technology, involving density gradient ultracentrifugation. The VAP lipid panel was marketed, assessing nine cardiovascular health markers. Testing services were supplied to physicians, hospitals, clinics, and laboratories across the United States. Operations were ceased in February 2016 due to financial challenges.
- Headquarters Birmingham, United States
- Employees 335
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website atherotech.com
- Social LinkedIn X Facebook
- Acquired by Behrman Capital (Jan 2011)
- Legal Name Atherotech, Inc.
- Latest Funding Round$999.13K (USD), Unspecified
Oct 2009
- InvestorsPharos Capital Group
& 1 more
- Employee Count335
- Acquired byBehrman Capital
(Jan 2011)
Products & Services of Atherotech
Atherotech offers a comprehensive portfolio of products and services, including News Platform and Newsletter Service.
Offers articles on medical tech and health innovations
Provides updates on health news and technology
Funding Insights of Atherotech
- Total Rounds 2
- Last Round Unspecified — $999,131
- Investors Count 1
All 2 funding rounds of Atherotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2009 | $999,131 | Unspecified | – | – | – |
| Jun 2002 | Unspecified | – | – |
2 investors in total: 2 institutional.
Investors in Atherotech
Atherotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Pharos Capital Group and Behrman Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are made to improve patient outcomes. | 1998 | pharosfunds.com | Dallas, United States | |
Private equity firm investing in buyouts of growth companies | behrmancap.com | New York, United States |
Investor details for Atherotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Atherotech
4 dated milestones of Atherotech across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Atherotech is founded.
- Funding First funding round.
- Funding Latest funding round, Unspecified, of $999K.
- Exit Acquired by Behrman Capital.
Competitors of Atherotech
Atherotech has 3 listed competitors in our database, 3 of them funded. They include SpectraWAVE, Proxim Diagnostics and Boston Heart Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| spectrawave.com | 2012 | Waltham, United States | $79.88M | 36 | Photonic imaging diagnostics for cardiovascular disease treatment are provided. | |
| proximdx.com | 2010 | Sunnyvale, United States | $22.9M | Handheld immunodiagnostic devices for cardiac vascular diseases are developed. | ||
| bostonheartdiagnostics.com | 2007 | Framingham, United States | $10.34M | Diagnostics for personalized cardiovascular disease management are developed. |
Detailed competitors of Atherotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Atherotech
Websites that share an audience with Atherotech (atherotech.com).
Websites whose visitors overlap most with Atherotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clevelandheartlab.com | 100% | 23.1K | #1,301,267 | View details | |
en.wikipedia.org | en.wikipedia.org | 96% | – | ||
cholesterol.about.com | cholesterol.about.com | 76% | – |
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Atherotech (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Atherotech
Atherotech was founded in 1994 and raised its 1st funding round 8 years after it was founded.
Atherotech is headquartered in Birmingham, United States. It is registered at Birmingham, Alabama, United States.
Atherotech has 335 employees.
Atherotech was founded in 1994 in Birmingham, United States, within the healthcare sector. Comprehensive lipid profiles were measured directly through the patented VAP technology, involving density gradient ultracentrifugation. The VAP lipid panel was marketed, assessing nine cardiovascular health markers. Testing services were supplied to physicians, hospitals, clinics, and laboratories across the United States. Operations were ceased in February 2016 due to financial challenges.
Atherotech's top competitors include SpectraWAVE, Boston Heart Diagnostics and Proxim Diagnostics.
Atherotech offers News Platform and Newsletter Service.
Atherotech has 2 investors. Key investors include Pharos Capital Group, and Behrman Capital.
Atherotech operates through Atherotech, Inc..
Yes. Atherotech was acquired by Behrman Capital in January 2011.